ARID1A and gastric cancer: To evaluate the effect of lost ARID1A on the efficiency of EBV infection, ARID1A was knocked down with siRNA in the EBV-negative gastric cancer cell lines MKN74 and NUGC3, followed by cell-to-cell contact infection using the Akata infection system.